Litton JK, Hurvitz SA, Mina LA, Rugo HS, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol 2020 Aug 20. pii: S0923-7534(20)42106.
PMID: 32828825